Organovo Logo (2 Color Med-Res-082117).png
Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel Disease
21 mai 2024 08h05 HE | Organovo, Inc.
Poster presented at DDW2024 demonstrating the potential of the Company’s clinical-stage compound, FXR314, in combination with tofacitinib for treating IBD.
Fractyl-Logo.png
Fractyl Health Presents Compelling Preclinical Data from Single-Administration GLP-1 Pancreatic Gene Therapy Rejuva® at Digestive Disease Week 2024
20 mai 2024 06h00 HE | Fractyl Health, Inc.
Fractyl Health Presents Compelling Preclinical Data from Single-Administration GLP-1 Pancreatic Gene Therapy Rejuva® at Digestive Disease Week 2024
Organovo Logo (2 Color Med-Res-082117).png
Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024)
14 mai 2024 11h00 HE | Organovo, Inc.
Organovo will be presenting data on the Company’s lead clinical-stage drug, FXR314 during DDW2024, which is being held in Washington, D.C. May 18-21, 2024
Rani-Logo.jpg
Rani Therapeutics to Present Clinical and Preclinical Data on Oral Delivery of an Ustekinumab Biosimilar via the RaniPill® Capsule at Digestive Disease Week 2024
09 mai 2024 08h00 HE | Rani Therapeutics, LLC
SAN JOSE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...
Fractyl-Logo.png
Fractyl Health Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference and the German Diabetes Association (DDG) Annual Meeting
30 avr. 2024 08h38 HE | Fractyl Health, Inc.
Fractyl Health Announces Multiple Presentations at DDW 2024 Conference and the German Diabetes Association (DDG) Annual Meeting